Sangamo BioSciences | SGMO - Cash And Equivalent


Sangamo BioSciences reported $38.34M in Cash and Equivalent for its fiscal quarter ending in June of 2025.





Cash And Equivalent Change Date
Alaunos Therapeutics USD 354K 1.03M Mar/2026
Alnylam Pharmaceuticals USD 1.71B 2.46M Jun/2026
Alterity Therapeutics Limited AUD 15.77M 9.56M Jun/2023
Amgen USD 13.99B 1.95B Jun/2026
Bayer EUR 4.29B 1.44B Jun/2026
BioCryst Pharmaceuticals USD 154.97M 16.62M Jun/2026
Biogen USD 1.28B 2.1B Jun/2026
BioMarin Pharmaceutical USD 874M 1.35B Jun/2026
Cipla INR 10.18B 2.22B Mar/2026
Clal Biotechnology ILS 5.73M 1.71M Dec/2023
Compugen USD 12.43M 78.16M Mar/2026
CSL USD 2.16B 633M Jun/2025
Gilead Sciences USD 7.63B 64M Mar/2026
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Grifols EUR 979.78M 334.84M Dec/2024
Ionis Pharmaceuticals USD 350.06M 1.57B Jun/2026
J&J USD 20.42B 1.27B Jun/2026
Karyopharm Therapeutics USD 90.85M 30.31M Mar/2026
Merck USD 6.85B 1.52B Jun/2026
Novartis USD 7.62B 739M Jun/2026
Omeros USD 1.9M 2.36M Jun/2025
Pfizer USD 976M 727M Jun/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Sanofi EUR 6.35B 806M Jun/2026
Sarepta Therapeutics USD 571.15M 106.7M Jun/2026
Tectonic Therapeutic USD 236.89M 16.9M Mar/2026
Ultragenyx Pharmaceutical USD 125M 50M Jun/2026
Vertex Pharmaceuticals USD 7.85B 605.7M Jun/2026